Full View

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

ANJ Tutt, JE Garber, B Kaufman, G Viale… - … England Journal of …, 2021 - Mass Medical Soc
Background Poly (adenosine diphosphate–ribose) polymerase inhibitors target cancers with
defects in homologous recombination repair by synthetic lethality. New therapies are …
被引用次数：1092 相关文章

Adjuvant Olaparib for Patients with BRCA1-or BRCA2-Mutated Breast Cancer

ANJ Tutt, JE Garber, B Kaufman, G Viale… - N. Engl. J …, 2021 - kups.ub.uni-koeln.de
BACKGROUND Poly (adenosine diphosphate-ribose) polymerase inhibitors target cancers
with defects in homologous recombination repair by synthetic lethality. New therapies are …

Adjuvant Olaparib for Patients with BRCA1-or BRCA2-Mutated Breast Cancer.

ANJ Tutt, JE Garber, B Kaufman, G Viale… - The New England …, 2021 - boris.unibe.ch
BACKGROUND Poly (adenosine diphosphate-ribose) polymerase inhibitors target cancers
with defects in homologous recombination repair by synthetic lethality. New therapies are …

[引用][C] Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer

ANJ Tutt, JE Garber, B Kaufman… - … England Journal of …, 2021 - espace.library.uq.edu.au
BACKGROUND Poly (adenosine diphosphate–ribose) polymerase inhibitors target cancers
with defects in homologous recombination repair by synthetic lethality. New therapies are …

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

ANJ Tutt, JE Garber, B Kaufman, G Viale… - New England Journal …, 2021 - cir.nii.ac.jp
Adjuvant Olaparib for Patients with <i>BRCA1</i>- or <i>BRCA2</i>-Mutated Breast Cancer
| CiNii Research CiNii 国立情報学研究所 学術情報ナビゲータ[サイニィ] 詳細へ移動 検索 …

Adjuvant Olaparib for Patients with BRCA1-or BRCA2-Mutated Breast Cancer

ANJ Tutt, JE Garber, B Kaufman, G Viale… - NEW ENGLAND …, 2021 - air.unimi.it
BACKGROUNDPoly (adenosine diphosphate-ribose) polymerase inhibitors target cancers
with defects in homologous recombination repair by synthetic lethality. New therapies are …

Adjuvant olaparib for patients with BRCA1-or BRCA2-mutated breast cancer

ANJ Tutt, JE Garber, B Kaufman… - New England …, 2021 - scholarlypublications …
BACKGROUNDPoly (adenosine diphosphate-ribose) polymerase inhibitors target cancers
with defects in homologous recombination repair by synthetic lethality. New therapies are …

Adjuvant Olaparib for Patients with BRCA1-or BRCA2-Mutated Breast Cancer.

ANJ Tutt, JE Garber, B Kaufman, G Viale, D Fumagalli… - 2021 - repository.icr.ac.uk
BACKGROUND: Poly (adenosine diphosphate-ribose) polymerase inhibitors target cancers
with defects in homologous recombination repair by synthetic lethality. New therapies are …

Adjuvant olaparib for patients with BRCA1-Or BRCA2-mutated breast cancer

ANJ Tutt, JE Garber, B Kaufman, G Viale… - New England Journal …, 2021 - kclpure.kcl.ac.uk
BACKGROUND Poly (adenosine diphosphate–ribose) polymerase inhibitors target cancers
with defects in homologous recombination repair by synthetic lethality. New therapies are …
[HTML] nih.gov

[HTML][HTML] Adjuvant Olaparib for Patients with BRCA1-or BRCA2-Mutated Breast Cancer

ANJ Tutt, JE Garber, B Kaufman, G Viale… - The New England …, 2021 - ncbi.nlm.nih.gov
BACKGROUND Poly (adenosine diphosphate–ribose) polymerase inhibitors target cancers
with defects in homologous recombination repair by synthetic lethality. New therapies are …